The company said Friday it develops medicines designed to precisely target disease pathology with an initial emphasis on the innate immune system. Odyssey said its most advanced programs include ...
Jefferies analyst Stephen Volkmann maintained a Buy rating on Ingersoll Rand (IR – Research Report) yesterday and set a price target of ...
In a report released today, Kelly Shi from Jefferies assigned a Buy rating to Summit Therapeutics (SMMT – Research Report), with a price target ...
Hosted on MSN22h
UnitedHealth Group Earnings Transcript (NYSE:UNH)Presentation Operator Good morning, and welcome to UnitedHealth Group Fourth Quarter and Full Year 2024 Earnings Conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback